ReviewMediterranean journal of rheumatology2026
Current and Emerging Therapies for Uveitis in Axial Spondyloarthritis: A Scoping Review.
Review in Mediterranean journal of rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Comparison of the Risk of Acute Anterior Uveitis Flare Between Adalimumab and Subcutaneous Infliximab in Patients with Radiographic Axial Spondyloarthritis and Prior Acute Anterior Uveitis: A Randomized Controlled Trial.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Trial
- Uveitis in spondyloarthritis: clinical patterns and differences between axial and peripheral forms.Clinical rheumatology · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: Uveitis is a common and potentially vision-threatening extra-musculoskeletal manifestation of axial spondyloarthritis (axSpA). Various biologic (bDMARD), as well as targeted synthetic (tsDMARD) disease-modifying anti-rheumatic drugs are established treatment options not only for axSpA, but for the whole spectrum of Spondyloarthritides. However, evidence from randomised-controlled trials (RCTs) specifically designed to assess axSpA-related uveitis treatment efficacy remains scarce, with the majority of evidence being extrapolated from RCTs with musculoskeletal orientation. This review examines current and emerging treatment options for axSpA-related uveitis, emphasising existing evidence gaps and clinical uncertainties. Methods: A scoping literature review was conducted following the PRISMA guidelines. PubMed, Scopus, and Cochrane databases were searched, according to the prespecified protocol criteria. After inaugural screening, eligible studies were evaluated performing quality assessment for final inclusion. Results: 55 studies were retrieved and finally included. Studies were published between 2002-2025. Uveitis exposure-adjusted incidence rates per 100 patient years (EAIR/100PY) ranged between 0-4.5 for tumour necrosis factor inhibitors (TNFi), 0.5-3.9 for interleukin-17 inhibitors (IL-17i) and 0.8-3.3 for upadacitinib (UPA), as derived from available RCTs. Evidence from non-RCTs, reporting uveitis incidence rates per 100PY, ranged between 3.46-55.2 for etanercept, 1.38-15.7 for adalimumab, 1.82-25.9 for infliximab, 1.39-6.8 for golimumab, 0-9.4 for secukinumab and 0 for ixekizumab. Conclusion: Monoclonal TNFi are still the preferred therapeutic choice in axSpA patients with prior or high risk of uveitis. IL-17i are identified as second line treatment option especially in uveitis refractory to TNFi. Finally, JAKi remain a promising alternative, with more evidence needed to further establish their so far proven efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.